Research	O
prioritization	O
through	O
prediction	O
of	O
future	O
impact	O
on	O
biomedical	O
science	O
:	O
a	O
position	O
paper	O
on	O
inference	O
-	O
analytics	O

Background	O

Advances	O
in	O
biotechnology	O
have	O
created	O
“	O
big	O
-	O
data	O
”	O
situations	O
in	O
molecular	O
and	O
cellular	O
biology	O
.	O

Several	O
sophisticated	O
algorithms	O
have	O
been	O
developed	O
that	O
process	O
big	O
data	O
to	O
generate	O
hundreds	O
of	O
biomedical	O
hypotheses	O
(	O
or	O
predictions	O
).	O

The	O
bottleneck	O
to	O
translating	O
this	O
large	O
number	O
of	O
biological	O
hypotheses	O
is	O
that	O
each	O
of	O
them	O
needs	O
to	O
be	O
studied	O
by	O
experimentation	O
for	O
interpreting	O
its	O
functional	O
significance	O
.	O

Even	O
when	O
the	O
predictions	O
are	O
estimated	O
to	O
be	O
very	O
accurate	O
,	O
from	O
a	O
biologist	O
’	O
s	O
perspective	O
,	O
the	O
choice	O
of	O
which	O
of	O
these	O
predictions	O
is	O
to	O
be	O
studied	O
further	O
is	O
made	O
based	O
on	O
factors	O
like	O
availability	O
of	O
reagents	O
and	O
resources	O
and	O
the	O
possibility	O
of	O
formulating	O
some	O
reasonable	O
hypothesis	O
about	O
its	O
biological	O
relevance	O
.	O

When	O
viewed	O
from	O
a	O
global	O
perspective	O
,	O
say	O
from	O
that	O
of	O
a	O
federal	O
funding	O
agency	O
,	O
ideally	O
the	O
choice	O
of	O
which	O
prediction	O
should	O
be	O
studied	O
would	O
be	O
made	O
based	O
on	O
which	O
of	O
them	O
can	O
make	O
the	O
most	O
translational	O
impact	O
.	O

Results	O

We	O
propose	O
that	O
algorithms	O
be	O
developed	O
to	O
identify	O
which	O
of	O
the	O
computationally	O
generated	O
hypotheses	O
have	O
potential	O
for	O
high	O
translational	O
impact	O
;	O
this	O
way	O
,	O
funding	O
agencies	O
and	O
scientific	O
community	O
can	O
invest	O
resources	O
and	O
drive	O
the	O
research	O
based	O
on	O
a	O
global	O
view	O
of	O
biomedical	O
impact	O
without	O
being	O
deterred	O
by	O
local	O
view	O
of	O
feasibility	O
.	O

In	O
short	O
,	O
data	O
-	O
analytic	O
algorithms	O
analyze	O
big	O
-	O
data	O
and	O
generate	O
hypotheses	O
;	O
in	O
contrast	O
,	O
the	O
proposed	O
inference	O
-	O
analytic	O
algorithms	O
analyze	O
these	O
hypotheses	O
and	O
rank	O
them	O
by	O
predicted	O
biological	O
impact	O
.	O

We	O
demonstrate	O
this	O
through	O
the	O
development	O
of	O
an	O
algorithm	O
to	O
predict	O
biomedical	O
impact	O
of	O
protein	O
-	O
protein	O
interactions	O
(	O
PPIs	O
)	O
which	O
is	O
estimated	O
by	O
the	O
number	O
of	O
future	O
publications	O
that	O
cite	O
the	O
paper	O
which	O
originally	O
reported	O
the	O
PPI	O
.	O

Conclusions	O

This	O
position	O
paper	O
describes	O
a	O
new	O
computational	O
problem	O
that	O
is	O
relevant	O
in	O
the	O
era	O
of	O
big	O
-	O
data	O
and	O
discusses	O
the	O
challenges	O
that	O
exist	O
in	O
studying	O
this	O
problem	O
,	O
highlighting	O
the	O
need	O
for	O
the	O
scientific	O
community	O
to	O
engage	O
in	O
this	O
line	O
of	O
research	O
.	O

The	O
proposed	O
class	O
of	O
algorithms	O
,	O
namely	O
inference	O
-	O
analytic	O
algorithms	O
,	O
is	O
necessary	O
to	O
ensure	O
that	O
resources	O
are	O
invested	O
in	O
translating	O
those	O
computational	O
outcomes	O
that	O
promise	O
maximum	O
biological	O
impact	O
.	O

Application	O
of	O
this	O
concept	O
to	O
predict	O
biomedical	O
impact	O
of	O
PPIs	O
illustrates	O
not	O
only	O
the	O
concept	O
,	O
but	O
also	O
the	O
challenges	O
in	O
designing	O
these	O
algorithms	O
.	O

Background	O

Big	O
data	O
is	O
everywhere	O
today	O
,	O
be	O
it	O
data	O
from	O
publications	O
(	O
newspapers	O
,	O
journals	O
,	O
internet	O
pages	O
or	O
tweets	O
),	O
or	O
be	O
it	O
cosmological	O
,	O
climatic	O
,	O
or	O
ecological	O
data	O
.	O

This	O
trend	O
is	O
facilitated	O
primarily	O
by	O
the	O
exponential	O
increases	O
in	O
the	O
capabilities	O
of	O
computing	O
,	O
storage	O
and	O
communication	O
technologies	O
.	O

In	O
biology	O
,	O
advances	O
in	O
biotechnology	O
have	O
resulted	O
in	O
the	O
creation	O
of	O
big	O
data	O
of	O
many	O
types	O
:	O
genomic	O
,	O
proteomic	O
,	O
trascriptomic	O
,	O
epigenomic	O
and	O
metabolomic	O
characterizations	O
of	O
several	O
species	O
and	O
their	O
populations	O
.	O

Large	O
-	O
scale	O
data	O
analytics	O
can	O
aid	O
in	O
discovering	O
patterns	O
in	O
these	O
data	O
to	O
gain	O
new	O
scientific	O
insights	O
;	O
however	O
,	O
the	O
domain	O
of	O
biology	O
is	O
very	O
different	O
from	O
most	O
other	O
domains	O
in	O
this	O
aspect	O
.	O

Validating	O
a	O
computational	O
result	O
is	O
cheap	O
in	O
domains	O
like	O
language	O
translation	O
,	O
and	O
can	O
be	O
carried	O
out	O
by	O
any	O
average	O
individual	O
;	O
when	O
the	O
number	O
of	O
results	O
is	O
in	O
hundreds	O
or	O
thousands	O
,	O
it	O
is	O
possible	O
to	O
crowdsource	O
the	O
validations	O
using	O
Amazon	O
MechanicalTurk	O
[	O
1	O
]	O
or	O
the	O
like	O
.	O

Manual	O
validators	O
can	O
often	O
correct	O
mistakes	O
of	O
the	O
algorithm	O
,	O
and	O
these	O
corrections	O
may	O
in	O
turn	O
be	O
used	O
to	O
improve	O
the	O
algorithm	O
in	O
future	O
.	O

Secondly	O
,	O
the	O
computational	O
results	O
are	O
often	O
ready	O
for	O
direct	O
use	O
or	O
interpretation	O
.	O

For	O
example	O
,	O
outcomes	O
of	O
algorithms	O
for	O
machine	O
translation	O
from	O
one	O
language	O
to	O
another	O
,	O
information	O
retrieval	O
,	O
weather	O
prediction	O
,	O
etc	O
.	O
may	O
be	O
directly	O
deployed	O
for	O
use	O
in	O
real	O
life	O
.	O

Compared	O
to	O
these	O
domains	O
,	O
there	O
are	O
four	O
fundamental	O
differences	O
in	O
large	O
-	O
scale	O
data	O
analytics	O
for	O
molecular	O
and	O
cellular	O
biology	O
:	O

(	O
i	O
)	O
Conclusions	O
drawn	O
by	O
algorithms	O
cannot	O
be	O
validated	O
manually	O
,	O
and	O
often	O
require	O
carrying	O
out	O
experiments	O
.	O

(	O
ii	O
)	O
Even	O
when	O
the	O
computational	O
inferences	O
are	O
accurate	O
and	O
do	O
not	O
require	O
further	O
validation	O
,	O
converting	O
the	O
inferences	O
to	O
meaningful	O
insights	O
requires	O
experimentation	O
.	O

(	O
iii	O
)	O
Experimental	O
methods	O
require	O
resources	O
that	O
are	O
expensive	O
(	O
material	O
and	O
financial	O
resources	O
)	O
or	O
even	O
unavailable	O
(	O
suitable	O
antibodies	O
).	O

(	O
iv	O
)	O
Validation	O
and	O
interpretation	O
of	O
inferences	O
requires	O
scientific	O
expertise	O
which	O
may	O
be	O
scarce	O
(	O
for	O
example	O
,	O
there	O
may	O
not	O
be	O
any	O
scientist	O
with	O
expertise	O
in	O
studying	O
some	O
of	O
the	O
proteins	O
).	O

For	O
these	O
reasons	O
validating	O
or	O
interpreting	O
all	O
the	O
hundreds	O
of	O
computational	O
inferences	O
of	O
data	O
-	O
analytic	O
algorithms	O
is	O
expensive	O
and	O
is	O
not	O
amenable	O
to	O
crowdsourcing	O
.	O

In	O
this	O
position	O
paper	O
,	O
we	O
introduce	O
the	O
concept	O
called	O
inference	O
-	O
analytics	O
,	O
and	O
a	O
specific	O
inference	O
-	O
analytics	O
problem	O
called	O
impact	O
prediction	O
.	O

We	O
use	O
the	O
terms	O
predictions	O
,	O
computational	O
inferences	O
or	O
hypotheses	O
to	O
refer	O
to	O
the	O
outcomes	O
of	O
data	O
-	O
analytic	O
algorithms	O
.	O

Inference	O
analytics	O
for	O
research	O
prioritization	O

In	O
domains	O
such	O
as	O
biology	O
where	O
hypothesis	O
verification	O
and	O
interpretation	O
are	O
resource	O
-	O
intensive	O
,	O
the	O
large	O
number	O
of	O
inferences	O
drawn	O
by	O
data	O
-	O
analytic	O
algorithms	O
would	O
have	O
to	O
be	O
reanalyzed	O
by	O
various	O
criteria	O
such	O
as	O
availability	O
of	O
resources	O
(	O
budget	O
,	O
reagents	O
or	O
scientific	O
expertise	O
).	O

We	O
call	O
such	O
algorithms	O
which	O
re	O
-	O
analyze	O
data	O
analytic	O
inferences	O
as	O
inference	O
analytic	O
algorithms	O
(	O
Figure	O
1	O
);	O
an	O
inference	O
analytic	O
algorithm	O
that	O
is	O
essential	O
in	O
the	O
field	O
of	O
biology	O
is	O
that	O
of	O
predicting	O
the	O
future	O
impact	O
of	O
an	O
inference	O
on	O
biomedicine	O
.	O

Inference	O
analytics	O
.	O

(	O
A	O
)	O
Data	O
analytics	O
typically	O
analyze	O
large	O
datasets	O
to	O
draw	O
inferences	O
;	O
these	O
inferences	O
are	O
usually	O
used	O
directly	O
;	O
the	O
inferences	O
may	O
be	O
evaluated	O
with	O
relatively	O
small	O
investment	O
of	O
resources	O
or	O
through	O
crowdsourcing	O
.	O
(	O
B	O
)	O
In	O
areas	O
such	O
as	O
biology	O
,	O
it	O
is	O
desirable	O
that	O
data	O
analytics	O
is	O
followed	O
by	O
inference	O
analytics	O
;	O
these	O
algorithms	O
would	O
analyze	O
the	O
large	O
number	O
of	O
data	O
analytic	O
inferences	O
and	O
re	O
-	O
ranking	O
them	O
by	O
various	O
criteria	O
to	O
aid	O
the	O
users	O
in	O
selecting	O
which	O
inference	O
to	O
pursue	O
.	O

The	O
work	O
presented	O
here	O
corresponds	O
to	O
inference	O
analytics	O
for	O
“	O
scientific	O
impact	O
prediction	O
”	O
criterion	O
.	O

Predicting	O
future	O
impact	O
of	O
inferences	O
is	O
necessary	O
in	O
biology	O
and	O
biomedicine	O

Just	O
as	O
grant	O
proposals	O
are	O
evaluated	O
for	O
their	O
“	O
difference	O
making	O
capability	O
”	O
to	O
determine	O
priority	O
of	O
funding	O
,	O
the	O
inferences	O
drawn	O
at	O
a	O
large	O
scale	O
may	O
be	O
evaluated	O
by	O
their	O
potential	O
for	O
biomedical	O
impact	O
before	O
investing	O
resources	O
to	O
experimentally	O
study	O
them	O
(	O
Figure	O
1	O
).	O

Impact	O
prediction	O
,	O
or	O
ranking	O
the	O
computational	O
inferences	O
based	O
on	O
future	O
impact	O
is	O
distinct	O
from	O
other	O
methods	O
of	O
re	O
-	O
ranking	O
computational	O
outcomes	O
,	O
such	O
as	O
ranking	O
by	O
confidence	O
of	O
prediction	O
.	O

Here	O
,	O
we	O
assume	O
that	O
all	O
computational	O
outcomes	O
are	O
equally	O
accurate	O
,	O
and	O
propose	O
to	O
re	O
-	O
rank	O
them	O
by	O
their	O
predicted	O
impact	O
on	O
future	O
science	O
.	O

Impact	O
prediction	O
is	O
also	O
distinct	O
from	O
task	O
prioritization	O
,	O
a	O
well	O
-	O
studied	O
area	O
in	O
computer	O
science	O
.	O

Task	O
prioritization	O
assumes	O
that	O
priorities	O
and	O
costs	O
are	O
known	O
for	O
the	O
tasks	O
,	O
and	O
it	O
optimizes	O
allocation	O
of	O
resources	O
to	O
tasks	O
to	O
achieve	O
maximum	O
yield	O
.	O

Here	O
,	O
our	O
goal	O
is	O
to	O
predict	O
the	O
biomedical	O
impact	O
(	O
a	O
type	O
of	O
priority	O
)	O
so	O
that	O
resource	O
allocation	O
(	O
e	O
.	O
g	O
.,	O
by	O
a	O
funding	O
agency	O
)	O
can	O
be	O
carried	O
out	O
based	O
on	O
these	O
priorities	O
.	O

Citation	O
count	O
can	O
be	O
used	O
as	O
a	O
surrogate	O
measure	O
for	O
biomedical	O
impact	O

The	O
focus	O
of	O
this	O
work	O
is	O
on	O
estimating	O
the	O
biological	O
importance	O
of	O
a	O
specific	O
PPI	O
(	O
i	O
.	O
e	O
.,	O
how	O
central	O
is	O
a	O
PPI	O
towards	O
understanding	O
other	O
biological	O
or	O
disease	O
related	O
factors	O
).	O

How	O
do	O
we	O
measure	O
this	O
importance	O
?	O

Consider	O
the	O
publications	O
that	O
report	O
each	O
of	O
these	O
PPIs	O
;	O
then	O
consider	O
the	O
publications	O
that	O
cite	O
these	O
original	O
publications	O
.	O

In	O
this	O
narrow	O
domain	O
of	O
publications	O
reporting	O
or	O
citing	O
PPIs	O
,	O
we	O
estimate	O
that	O
each	O
article	O
typically	O
contains	O
one	O
primary	O
result	O
;	O
we	O
measure	O
the	O
importance	O
of	O
a	O
PPI	O
in	O
terms	O
of	O
how	O
many	O
papers	O
cite	O
the	O
original	O
publication	O
reporting	O
that	O
PPI	O
.	O

For	O
example	O
,	O
the	O
PPI	O
of	O
EGFR	B-GP
with	O
Actin	B-GP
was	O
central	O
in	O
advancing	O
our	O
knowledge	O
of	O
several	O
other	O
biological	O
concepts	O
discovered	O
based	O
on	O
this	O
PPI	O
.	O

For	O
this	O
reason	O
,	O
the	O
paper	O
reporting	O
this	O
PPI	O
[	O
2	O
]	O
has	O
been	O
cited	O
by	O
35	O
articles	O
in	O
PubMed	O
.	O

The	O
impact	O
of	O
EGFR	B-GP
-	O
Actin	B-GP
is	O
therefore	O
estimated	O
to	O
be	O
at	O
35	O
“	O
biomedical	O
results	O
”.	O

Thus	O
,	O
we	O
approximate	O
impact	O
prediction	O
with	O
citation	O
count	O
prediction	O
.	O

Citation	O
count	O
prediction	O
for	O
scientific	O
impact	O
is	O
different	O
from	O
citation	O
count	O
prediction	O
based	O
on	O
metadata	O

Several	O
researchers	O
have	O
investigated	O
predicting	O
the	O
citation	O
counts	O
for	O
scientific	O
papers	O
[	O
3	O
-	O
5	O
].	O

However	O
,	O
in	O
these	O
methods	O
only	O
metadata	O
about	O
the	O
publication	O
(	O
number	O
of	O
past	O
articles	O
and	O
past	O
citations	O
of	O
the	O
first	O
author	O
),	O
and	O
content	O
(	O
article	O
title	O
,	O
abstract	O
and	O
MeSH	O
terms	O
)	O
have	O
been	O
used	O
.	O

Our	O
work	O
differs	O
from	O
such	O
work	O
in	O
that	O
we	O
do	O
not	O
consider	O
citation	O
impact	O
based	O
on	O
reputation	O
of	O
the	O
journal	O
or	O
that	O
of	O
the	O
author	O
,	O
but	O
we	O
focus	O
on	O
the	O
biomedical	O
information	O
of	O
the	O
published	O
scientific	O
result	O
that	O
is	O
receiving	O
the	O
citations	O
.	O

Here	O
,	O
citation	O
counts	O
are	O
used	O
as	O
a	O
surrogate	O
measure	O
of	O
the	O
impact	O
of	O
a	O
scientific	O
result	O
.	O

Of	O
course	O
,	O
many	O
factors	O
influence	O
the	O
citing	O
behavior	O
of	O
a	O
given	O
paper	O
:	O
year	O
of	O
its	O
publication	O
,	O
the	O
journal	O
containing	O
the	O
publication	O
,	O
its	O
availability	O
and	O
accessibility	O
,	O
and	O
more	O
[	O
6	O
].	O

We	O
believe	O
that	O
the	O
original	O
publication	O
would	O
be	O
published	O
in	O
the	O
journal	O
it	O
deserves	O
(	O
e	O
.	O
g	O
.,	O
the	O
fact	O
that	O
a	O
paper	O
reporting	O
an	O
interaction	O
was	O
accepted	O
to	O
be	O
published	O
in	O
a	O
high	O
impact	O
journal	O
is	O
in	O
itself	O
an	O
indicator	O
that	O
the	O
interaction	O
may	O
be	O
of	O
high	O
biomedical	O
significance	O
);	O
therefore	O
,	O
the	O
bias	O
introduced	O
by	O
the	O
journal	O
of	O
publication	O
is	O
not	O
an	O
unwanted	O
bias	O
in	O
calculating	O
the	O
biomedical	O
impact	O
.	O

Other	O
factors	O
influencing	O
citation	O
counts	O
,	O
namely	O
the	O
year	O
of	O
publication	O
and	O
years	O
since	O
publication	O
are	O
addressed	O
to	O
some	O
extent	O
in	O
this	O
work	O
.	O

We	O
employ	O
citation	O
counts	O
as	O
indicators	O
of	O
“	O
future	O
impact	O
”	O
of	O
a	O
reported	O
biological	O
result	O
.	O

Predicting	O
impact	O
of	O
protein	O
-	O
protein	O
interactions	O

We	O
demonstrate	O
the	O
idea	O
of	O
inference	O
analytics	O
by	O
developing	O
an	O
algorithm	O
for	O
impact	O
prediction	O
in	O
the	O
domain	O
of	O
PPIs	O
.	O

We	O
propose	O
to	O
predict	O
the	O
impact	O
of	O
each	O
of	O
the	O
PPIs	O
,	O
so	O
that	O
experiments	O
may	O
be	O
prioritized	O
to	O
study	O
the	O
most	O
impactful	O
PPIs	O
.	O

Although	O
PPIs	O
form	O
the	O
basis	O
of	O
many	O
biological	O
phenomena	O
,	O
90	O
%	O
of	O
the	O
estimated	O
number	O
of	O
PPIs	O
are	O
currently	O
unknown	O
[	O
7	O
-	O
9	O
].	O

Extensive	O
research	O
is	O
being	O
carried	O
out	O
both	O
with	O
high	O
-	O
throughput	O
biotechnology	O
and	O
computational	O
methods	O
to	O
discover	O
PPIs	O
[	O
10	O
-	O
14	O
].	O

Both	O
these	O
approaches	O
provide	O
hundreds	O
or	O
thousands	O
of	O
hypothesized	O
PPIs	O
.	O

The	O
PPI	O
network	O
incorporating	O
these	O
thousands	O
of	O
newly	O
discovered	O
PPIs	O
is	O
useful	O
to	O
directly	O
carry	O
out	O
systems	O
biology	O
studies	O
[	O
15	O
-	O
19	O
].	O

However	O
,	O
to	O
advance	O
the	O
biology	O
surrounding	O
each	O
PPI	O
(	O
i	O
.	O
e	O
.,	O
to	O
translate	O
the	O
inference	O
into	O
biomedical	O
knowledge	O
),	O
many	O
detailed	O
experiments	O
need	O
to	O
be	O
performed	O
(	O
similar	O
to	O
the	O
experiments	O
that	O
reported	O
the	O
importance	O
of	O
EGFR	B-GP
-	O
Actin	B-GP
interaction	O
).	O

These	O
experiments	O
are	O
expensive	O
and	O
time	O
-	O
consuming	O
and	O
most	O
importantly	O
require	O
valuable	O
time	O
of	O
scientists	O
.	O

Selecting	O
a	O
PPI	O
for	O
experimental	O
study	O
is	O
usually	O
based	O
on	O
the	O
feasibility	O
(	O
availability	O
of	O
budget	O
,	O
reagents	O
,	O
time	O
and	O
technical	O
manpower	O
),	O
possibility	O
of	O
formulating	O
a	O
hypothesis	O
of	O
its	O
functional	O
significance	O
,	O
and	O
most	O
importantly	O
,	O
the	O
perceived	O
impact	O
of	O
its	O
validation	O
on	O
advancement	O
of	O
science	O
based	O
on	O
the	O
domain	O
knowledge	O
of	O
the	O
scientist	O
.	O

With	O
this	O
in	O
mind	O
,	O
it	O
is	O
infeasible	O
to	O
study	O
every	O
hypothesized	O
interaction	O
meticulously	O
with	O
detailed	O
experiments	O
due	O
to	O
the	O
sheer	O
number	O
of	O
the	O
inferred	O
interactions	O
.	O

When	O
viewed	O
from	O
a	O
global	O
perspective	O
,	O
say	O
by	O
a	O
funding	O
agency	O
that	O
has	O
the	O
capacity	O
to	O
drive	O
the	O
science	O
in	O
a	O
direction	O
that	O
is	O
important	O
,	O
the	O
selection	O
of	O
PPIs	O
for	O
experimentation	O
has	O
to	O
be	O
made	O
based	O
on	O
their	O
relative	O
expected	O
impact	O
.	O

There	O
should	O
be	O
a	O
mechanism	O
of	O
identifying	O
what	O
the	O
top	O
100	O
,	O
say	O
,	O
PPIs	O
are	O
that	O
are	O
most	O
urgent	O
because	O
of	O
their	O
potential	O
impact	O
on	O
biology	O
and	O
biomedicine	O
.	O

Existing	O
algorithms	O
generate	O
thousands	O
of	O
predictions	O
and	O
possibly	O
rank	O
them	O
by	O
confidence	O
,	O
but	O
none	O
currently	O
rank	O
them	O
by	O
the	O
impact	O
that	O
they	O
are	O
predicted	O
to	O
make	O
in	O
the	O
future	O

Data	O
description	O

Binary	O
biophysical	O
PPIs	O
in	O
human	B-OG
were	O
collected	O
from	O
HPRD	O
[	O
20	O
]	O
and	O
BioGRID	O
[	O
21	O
].	O

HPRD	O
gives	O
PPIs	O
as	O
a	O
list	O
of	O
“	O
binary	O
protein	O
-	O
protein	O
interactions	O
”,	O
and	O
BioGRID	O
gives	O
them	O
marked	O
with	O
the	O
identifier	O
“	O
MI	O
:	O
0407	O
”.	O

These	O
databases	O
present	O
PPIs	O
that	O
are	O
curated	O
from	O
publications	O
,	O
and	O
for	O
each	O
PPI	O
they	O
also	O
give	O
links	O
to	O
the	O
original	O
publication	O
(	O
s	O
)	O
that	O
reported	O
the	O
interaction	O
.	O

The	O
Entrez	O
Programming	O
Utilities	O
[	O
22	O
]	O
was	O
used	O
to	O
retrieve	O
citation	O
information	O
.	O

There	O
were	O
129	O
,	O
227	O
references	O
to	O
the	O
7	O
,	O
581	O
papers	O
that	O
had	O
one	O
-	O
to	O
-	O
one	O
relationship	O
with	O
interactions	O
.	O

17	O
,	O
985	O
of	O
them	O
were	O
self	O
-	O
references	O
(	O
13	O
.	O
92	O
%).	O

We	O
built	O
the	O
interactome	O
network	O
from	O
the	O
PPIs	O
,	O
and	O
computed	O
the	O
centrality	O
measures	O
of	O
PPIs	O
(	O
edges	O
)	O
and	O
the	O
participant	O
proteins	O
(	O
nodes	O
).	O

The	O
resulting	O
network	O
consists	O
of	O
10	O
,	O
492	O
nodes	O
and	O
48	O
,	O
419	O
edges	O
.	O

A	O
subset	O
of	O
PPIs	O
that	O
have	O
a	O
one	O
-	O
to	O
-	O
one	O
relation	O
with	O
PubMed	O
articles	O
(	O
i	O
.	O
e	O
.,	O
those	O
PPIs	O
that	O
are	O
reported	O
by	O
only	O
one	O
publication	O
and	O
where	O
that	O
publication	O
does	O
not	O
report	O
any	O
other	O
PPI	O
)	O
is	O
retrieved	O
to	O
be	O
considered	O
as	O
labeled	O
data	O
for	O
training	O
and	O
test	O
sets	O
.	O

Analyses	O

We	O
propose	O
a	O
computational	O
approach	O
to	O
find	O
the	O
most	O
promising	O
PPIs	O
,	O
and	O
we	O
measure	O
the	O
impact	O
of	O
a	O
PPI	O
in	O
terms	O
of	O
how	O
many	O
papers	O
cite	O
the	O
publication	O
that	O
originally	O
reported	O
the	O
PPI	O
.	O

Our	O
focus	O
is	O
on	O
estimating	O
the	O
biological	O
importance	O
of	O
a	O
PPI	O
;	O
and	O
we	O
therefore	O
base	O
our	O
predictions	O
on	O
the	O
topological	O
features	O
of	O
the	O
PPIs	O
with	O
respect	O
to	O
the	O
entire	O
interactome	O
.	O

We	O
frame	O
the	O
questions	O
as	O
follows	O
:	O
Is	O
there	O
a	O
detectable	O
trend	O
in	O
the	O
network	O
topology	O
of	O
highly	O
cited	O
interactions	O
or	O
are	O
they	O
placed	O
randomly	O
on	O
the	O
interactome	O
?	O

Do	O
interactions	O
with	O
high	O
biomedical	O
impact	O
have	O
unique	O
,	O
quantifiable	O
network	O
characteristics	O
that	O
distinguish	O
them	O
from	O
other	O
interactions	O
?	O

If	O
we	O
are	O
able	O
to	O
uncover	O
these	O
latent	O
characteristics	O
,	O
naturally	O
,	O
we	O
have	O
strong	O
reason	O
to	O
believe	O
that	O
we	O
should	O
study	O
interactions	O
in	O
the	O
order	O
of	O
their	O
predicted	O
importance	O
.	O

The	O
results	O
show	O
that	O
even	O
by	O
using	O
only	O
the	O
topological	O
features	O
of	O
PPIs	O
,	O
some	O
of	O
the	O
high	O
-	O
impact	O
PPIs	O
can	O
be	O
identified	O
.	O

Identifying	O
the	O
most	O
important	O
nodes	O
in	O
a	O
large	O
complex	O
network	O
has	O
been	O
well	O
-	O
studied	O
in	O
various	O
fields	O
.	O

In	O
the	O
field	O
of	O
sociology	O
,	O
various	O
centrality	O
measures	O
have	O
been	O
proposed	O
to	O
rank	O
the	O
nodes	O
in	O
a	O
complex	O
network	O
[	O
23	O
].	O

In	O
the	O
field	O
of	O
biology	O
,	O
these	O
centrality	O
measures	O
are	O
believed	O
to	O
determine	O
characteristics	O
of	O
protein	O
function	O
[	O
24	O
],	O
such	O
as	O
the	O
essentiality	O
of	O
the	O
gene	O
for	O
the	O
organism	O
’	O
s	O
survival	O
[	O
25	O
-	O
28	O
].	O

In	O
this	O
work	O
,	O
instead	O
of	O
identifying	O
the	O
most	O
important	O
nodes	O
in	O
a	O
network	O
,	O
we	O
consider	O
identifying	O
the	O
most	O
impactful	O
edges	O
in	O
a	O
network	O
.	O

Figure	O
2	O
shows	O
the	O
flow	O
diagram	O
of	O
this	O
work	O
which	O
includes	O
dataset	O
creation	O
,	O
construction	O
of	O
pair	O
-	O
wise	O
features	O
of	O
proteins	O
,	O
development	O
and	O
evaluation	O
of	O
the	O
proposed	O
model	O
,	O
and	O
the	O
application	O
of	O
the	O
model	O
to	O
predict	O
impact	O
of	O
all	O
PPIs	O
in	O
the	O
human	B-OG
interactome	O
.	O

PPI	O
data	O
.	O
From	O
the	O
human	B-OG
interactome	O
,	O
those	O
PPIs	O
(	O
edges	O
)	O
are	O
selected	O
that	O
have	O
1	O
–	O
1	O
relation	O
with	O
a	O
publication	O
;	O
that	O
is	O
,	O
the	O
publication	O
reports	O
only	O
one	O
interaction	O
,	O
and	O
that	O
interaction	O
is	O
not	O
reported	O
by	O
any	O
other	O
publication	O
.	O

The	O
classification	O
model	O
is	O
trained	O
and	O
evaluated	O
using	O
this	O
1	O
–	O
1	O
dataset	O
.	O

After	O
evaluating	O
the	O
approach	O
thus	O
,	O
all	O
of	O
the	O
1	O
–	O
1	O
dataset	O
is	O
used	O
to	O
train	O
a	O
new	O
model	O
which	O
is	O
then	O
used	O
to	O
classify	O
each	O
of	O
all	O
of	O
the	O
edges	O
in	O
the	O
interactome	O
to	O
identify	O
high	O
-	O
impact	O
edges	O
.	O

PPI	O
network	O
diagram	O
was	O
created	O
with	O
Cytoscape	O
[	O
29	O
-	O
31	O
].	O

Methods	O

Feature	O
representation	O

We	O
computed	O
network	O
centrality	O
measures	O
shown	O
in	O
Table	O
1	O
as	O
features	O
,	O
and	O
trained	O
a	O
random	O
forest	O
model	O
to	O
predict	O
high	O
-	O
impact	O
PPIs	O
.	O

Calculation	O
of	O
the	O
node	O
centralities	O
was	O
carried	O
out	O
using	O
the	O
Stanford	O
Network	O
Analysis	O
Library	O
[	O
32	O
],	O
and	O
of	O
the	O
edge	O
centrality	O
using	O
the	O
NetworkX	O
library	O
[	O
33	O
].	O

As	O
there	O
are	O
8	O
node	O
centrality	O
features	O
and	O
1	O
edge	O
centrality	O
feature	O
,	O
each	O
interaction	O
is	O
represented	O
by	O
a	O
vector	O
of	O
17	O
features	O
,	O
with	O
the	O
first	O
16	O
corresponding	O
to	O
the	O
node	O
centralities	O
of	O
the	O
two	O
proteins	O
and	O
the	O
17th	O
corresponding	O
to	O
the	O
edge	O
centrality	O
.	O

Let	O
D	O
=	O
[	O
X1	O
,	O
X2	O
,…,	O
Xn	O
]	O
represent	O
the	O
n	O
training	O
samples	O
and	O
Xi	O
=	O
x1i	O
,	O
x2i	O
,…,	O
x17i	O
,	O
yi	O
represent	O
the	O
i	O
-	O
th	O
sample	O
with	O
features	O
x	O
(	O
i	O
)	O
and	O
class	O
label	O
yi	O
As	O
PPIs	O
are	O
undirected	O
by	O
nature	O
,	O
and	O
node	O
centralities	O
are	O
features	O
that	O
pertain	O
to	O
nodes	O
(	O
proteins	O
),	O
special	O
care	O
must	O
be	O
taken	O
to	O
treat	O
each	O
interaction	O
as	O
an	O
unordered	O
pair	O
.	O

That	O
is	O
,	O
if	O
we	O
represent	O
an	O
interaction	O
between	O
proteins	O
a	O
and	O
b	O
by	O
an	O
ordered	O
pair	O
(	O
a	O
,	O
b	O
),	O
we	O
do	O
not	O
wish	O
to	O
discriminate	O
between	O
(	O
a	O
,	O
b	O
)	O
and	O
(	O
b	O
,	O
a	O
).	O

While	O
constructing	O
features	O
x	O
(	O
i	O
),	O
we	O
let	O
features	O
x1i	O
to	O
x8i	O
be	O
the	O
larger	O
values	O
of	O
the	O
two	O
node	O
centralities	O
,	O
and	O
let	O
features	O
x9i	O
to	O
x16i	O
be	O
the	O
smaller	O
value	O
of	O
the	O
two	O
,	O
in	O
order	O
to	O
symmetrize	O
the	O
feature	O
vectors	O
for	O
(	O
a	O
,	O
b	O
)	O
and	O
(	O
b	O
,	O
a	O
).	O

Calculated	O
centrality	O
measures	O

Feature	O
type	O

Feature	O

Node	O
centrality	O

Degree	O
centrality	O

Closeness	O
centrality	O

Betweenness	O
centrality	O
[	O
34	O
]	O

Eigenvector	O
centrality	O

Network	O
constraint	O

Clustering	O
coefficient	O

PageRank	O
[	O
35	O
]	O

Hub	O
centrality	O
(	O
authority	O
centrality	O
)	O

Edge	O
centrality	O

Brandes	O
’	O
betweeness	O
-	O
centrality	O
[	O
36	O
]	O

Models	O

Whether	O
an	O
interaction	O
is	O
labeled	O
positive	O
(	O
high	O
-	O
impact	O
)	O
or	O
negative	O
(	O
non	O
high	O
-	O
impact	O
),	O
is	O
defined	O
by	O
a	O
threshold	O
on	O
the	O
number	O
of	O
citations	O
.	O

For	O
a	O
given	O
threshold	O
t	O
,	O
a	O
positive	O
label	O
(	O
yi	O
=	O
1	O
)	O
means	O
that	O
the	O
paper	O
reporting	O
the	O
i	O
-	O
th	O
PPI	O
received	O
at	O
least	O
t	O
citations	O
within	O
the	O
5	O
-	O
year	O
window	O
following	O
the	O
publication	O
,	O
while	O
a	O
negative	O
label	O
(	O
yi	O
=	O
0	O
)	O
denotes	O
that	O
it	O
did	O
not	O
(	O
for	O
details	O
on	O
the	O
choice	O
of	O
the	O
5	O
-	O
year	O
window	O
,	O
see	O
Results	O
and	O
Discussion	O
).	O

The	O
threshold	O
was	O
set	O
to	O
5	O
,	O
10	O
,	O
30	O
and	O
50	O
in	O
this	O
study	O
.	O

Table	O
2	O
lists	O
the	O
number	O
of	O
positive	O
and	O
negative	O
instances	O
under	O
the	O
different	O
threshold	O
settings	O
.	O

Note	O
that	O
we	O
are	O
unable	O
to	O
use	O
interactions	O
reported	O
in	O
papers	O
published	O
less	O
than	O
5	O
years	O
prior	O
to	O
this	O
study	O
in	O
the	O
training	O
or	O
test	O
data	O
because	O
we	O
are	O
considering	O
the	O
citation	O
count	O
of	O
a	O
paper	O
within	O
a	O
5	O
-	O
year	O
window	O
following	O
the	O
publication	O
.	O

The	O
number	O
of	O
positive	O
/	O
negative	O
instances	O
and	O
their	O
ratio	O
under	O
the	O
different	O
threshold	O
settings	O
in	O
our	O
dataset	O

Threshold	O

Positive	O

Negative	O

npositive	O
/	O
ntotal	O

5	O

3	O
,	O
393	O

3	O
,	O
474	O

0	O
.	O
494	O

10	O

1	O
,	O
686	O

5	O
,	O
181	O

0	O
.	O
246	O

30	O

267	O

6	O
,	O
880	O

0	O
.	O
039	O

50	O

93	O

6	O
,	O
774	O

0	O
.	O
014	O

Random	O
Forest	O
from	O
the	O
Scikit	O
-	O
Learn	O
machine	O
learning	O
library	O
was	O
used	O
for	O
classification	O
[	O
37	O
-	O
39	O
].	O

Random	O
Forest	O
has	O
a	O
high	O
prediction	O
accuracy	O
for	O
many	O
types	O
of	O
data	O
achieved	O
by	O
using	O
bagging	O
on	O
samples	O
,	O
random	O
subsets	O
of	O
features	O
,	O
and	O
a	O
majority	O
voting	O
scheme	O
,	O
and	O
has	O
been	O
successfully	O
applied	O
to	O
various	O
problems	O
in	O
computational	O
biology	O
[	O
40	O
].	O

Random	O
forest	O
also	O
allows	O
the	O
estimation	O
of	O
feature	O
importance	O
[	O
38	O
].	O

Evaluation	O

Prior	O
works	O
in	O
citation	O
prediction	O
have	O
often	O
used	O
the	O
Receiver	O
Operating	O
Characteristic	O
(	O
ROC	O
)	O
[	O
4	O
]	O
or	O
accuracy	O
[	O
5	O
]	O
to	O
evaluate	O
their	O
methods	O
.	O

However	O
,	O
ROC	O
curves	O
can	O
present	O
an	O
overly	O
optimistic	O
view	O
of	O
an	O
algorithm	O
’	O
s	O
performance	O
if	O
there	O
is	O
a	O
large	O
skew	O
in	O
the	O
class	O
distribution	O
[	O
41	O
].	O

The	O
same	O
holds	O
for	O
accuracy	O
measure	O
.	O

For	O
our	O
task	O
,	O
because	O
there	O
are	O
much	O
more	O
negative	O
instances	O
than	O
positive	O
instances	O
,	O
we	O
use	O
precision	O
and	O
recall	O
,	O
and	O
the	O
area	O
under	O
the	O
precision	O
-	O
recall	O
curve	O
(	O
AUPR	O
)	O
to	O
compare	O
methods	O
.	O

For	O
our	O
prediction	O
task	O
,	O
we	O
are	O
mainly	O
interested	O
in	O
conditions	O
where	O
the	O
false	O
positive	O
rate	O
is	O
low	O
.	O

Thus	O
,	O
we	O
also	O
use	O
R50	O
,	O
a	O
partial	O
AUPR	O
score	O
that	O
measures	O
the	O
area	O
under	O
the	O
precision	O
-	O
recall	O
curve	O
until	O
reaching	O
50	O
negative	O
predictions	O
.	O

We	O
perform	O
a	O
10	O
-	O
fold	O
cross	O
-	O
validation	O
in	O
20	O
randomly	O
repeated	O
runs	O
to	O
obtain	O
average	O
values	O
.	O

We	O
repeat	O
cross	O
-	O
validation	O
runs	O
since	O
noise	O
exists	O
in	O
both	O
features	O
and	O
labels	O
;	O
as	O
we	O
shall	O
explain	O
later	O
,	O
our	O
features	O
are	O
calculated	O
from	O
a	O
sampled	O
sub	O
-	O
network	O
and	O
thus	O
inherently	O
contain	O
noise	O
.	O

The	O
averaged	O
performance	O
scores	O
are	O
used	O
for	O
comparison	O
.	O

We	O
compare	O
the	O
random	O
forest	O
model	O
against	O
a	O
random	O
method	O
,	O
in	O
which	O
we	O
assign	O
random	O
probability	O
sampled	O
from	O
a	O
continuous	O
uniform	O
distribution	O
from	O
the	O
interval	O
(	O
0	O
,	O
1	O
)	O
to	O
each	O
interaction	O
.	O

Application	O
to	O
all	O
PPIs	O
in	O
the	O
human	B-OG
interactome	O

After	O
evaluation	O
of	O
the	O
approach	O
,	O
a	O
new	O
model	O
is	O
trained	O
using	O
all	O
the	O
PPIs	O
with	O
one	O
-	O
to	O
-	O
one	O
relation	O
(	O
i	O
.	O
e	O
.,	O
combined	O
training	O
and	O
testing	O
datasets	O
previously	O
used	O
for	O
evaluation	O
).	O

This	O
model	O
is	O
employed	O
to	O
each	O
PPI	O
in	O
the	O
human	B-OG
interactome	O
to	O
predict	O
whether	O
it	O
is	O
likely	O
to	O
have	O
high	O
impact	O
(	O
Figure	O
2	O
).	O

Discussion	O

Figures	O
3	O
and	O
4	O
show	O
the	O
distribution	O
of	O
how	O
many	O
PPIs	O
are	O
reported	O
in	O
a	O
paper	O
,	O
and	O
the	O
distribution	O
of	O
how	O
many	O
papers	O
report	O
a	O
PPI	O
,	O
respectively	O
.	O

Most	O
papers	O
report	O
a	O
few	O
interactions	O
,	O
but	O
there	O
are	O
some	O
cases	O
where	O
a	O
single	O
paper	O
reports	O
multiple	O
PPIs	O
.	O

This	O
is	O
due	O
to	O
the	O
fact	O
that	O
HPRD	O
and	O
BioGRID	O
capture	O
all	O
interactions	O
in	O
a	O
paper	O
,	O
even	O
if	O
they	O
are	O
not	O
the	O
main	O
focus	O
of	O
an	O
experiment	O
.	O

We	O
excluded	O
the	O
manuscripts	O
that	O
report	O
a	O
large	O
number	O
of	O
PPIs	O
from	O
training	O
and	O
test	O
data	O
as	O
we	O
do	O
not	O
know	O
which	O
PPIs	O
contributed	O
to	O
the	O
citation	O
counts	O
;	O
the	O
publication	O
may	O
even	O
have	O
been	O
cited	O
for	O
the	O
methodology	O
(	O
such	O
as	O
yeast	B-OG
2	O
-	O
hybrid	O
or	O
an	O
algorithm	O
).	O

Similarly	O
,	O
we	O
excluded	O
PPIs	O
and	O
corresponding	O
manuscripts	O
where	O
a	O
specific	O
PPI	O
has	O
been	O
reported	O
by	O
multiple	O
manuscripts	O
.	O

This	O
leaves	O
7	O
,	O
581	O
interactions	O
among	O
5	O
,	O
182	O
unique	O
proteins	O
for	O
training	O
and	O
testing	O
the	O
model	O
.	O

Note	O
that	O
the	O
centrality	O
measures	O
are	O
computed	O
by	O
considering	O
the	O
entire	O
set	O
of	O
PPIs	O
and	O
not	O
just	O
this	O
subset	O
.	O

Precision	O
-	O
recall	O
curve	O
.	O
Average	O
precision	O
-	O
recall	O
curves	O
are	O
shown	O
for	O
the	O
two	O
methods	O
at	O
thresholds	O
of	O
5	O
,	O
10	O
,	O
30	O
and	O
50	O
.	O

The	O
blue	O
solid	O
line	O
corresponds	O
to	O
the	O
random	O
forest	O
model	O
.	O

The	O
red	O
dashed	O
line	O
corresponds	O
to	O
the	O
random	O
probability	O
assignment	O
.	O

Distribution	O
of	O
the	O
number	O
of	O
PPIs	O
reported	O
in	O
a	O
paper	O
.	O

We	O
studied	O
the	O
trends	O
of	O
citation	O
of	O
the	O
papers	O
that	O
report	O
PPIs	O
and	O
investigated	O
whether	O
there	O
is	O
any	O
inherent	O
pattern	O
that	O
underlies	O
the	O
citation	O
behavior	O
for	O
papers	O
that	O
report	O
interactions	O
.	O

Figure	O
5	O
shows	O
the	O
temporal	O
citation	O
pattern	O
for	O
the	O
7	O
,	O
581	O
papers	O
,	O
separated	O
by	O
the	O
publication	O
year	O
.	O

Regardless	O
of	O
the	O
publication	O
year	O
,	O
most	O
papers	O
tend	O
to	O
have	O
a	O
citation	O
peak	O
within	O
the	O
first	O
5	O
years	O
after	O
its	O
publication	O
.	O

Interestingly	O
,	O
there	O
is	O
a	O
second	O
peak	O
after	O
the	O
5	O
-	O
year	O
window	O
,	O
which	O
corresponds	O
to	O
citations	O
from	O
2010	O
to	O
2012	O
.	O

It	O
is	O
unclear	O
what	O
the	O
reason	O
for	O
this	O
citation	O
peak	O
is	O
.	O

It	O
may	O
be	O
due	O
to	O
the	O
Open	O
Access	O
policy	O
adopted	O
by	O
many	O
journals	O
,	O
authors	O
and	O
funding	O
agencies	O
which	O
started	O
a	O
couple	O
of	O
years	O
prior	O
to	O
2010	O
,	O
giving	O
the	O
time	O
for	O
other	O
researchers	O
to	O
access	O
the	O
papers	O
and	O
cite	O
them	O
in	O
their	O
work	O
.	O

Distribution	O
of	O
the	O
number	O
of	O
papers	O
that	O
report	O
a	O
PPI	O
.	O

Table	O
3	O
shows	O
the	O
results	O
of	O
the	O
model	O
in	O
comparison	O
to	O
random	O
baseline	O
.	O

The	O
random	O
forest	O
model	O
with	O
node	O
and	O
edge	O
centrality	O
features	O
consistently	O
outperforms	O
random	O
assignment	O
at	O
all	O
threshold	O
levels	O
with	O
a	O
significance	O
of	O
P	O
<	O
0	O
.	O
01	O
by	O
the	O
Wilcoxon	O
signed	O
-	O
rank	O
test	O
.	O

Figure	O
5	O
compares	O
the	O
average	O
precision	O
-	O
recall	O
curves	O
of	O
the	O
random	O
forest	O
model	O
and	O
random	O
assignment	O
for	O
the	O
different	O
threshold	O
settings	O
.	O

Results	O
on	O
the	O
dataset	O

Threshold	O

Method	O

AUPR	O

R50	O

5	O

Random	O
forest	O

0	O
.	O
5718	O

0	O
.	O
1450	O

Random	O

0	O
.	O
4975	O

0	O
.	O
0661	O

10	O

Random	O
forest	O

0	O
.	O
3204	O

0	O
.	O
0762	O

Random	O

0	O
.	O
2510	O

0	O
.	O
0272	O

30	O

Random	O
forest	O

0	O
.	O
0868	O

0	O
.	O
0426	O

Random	O

0	O
.	O
0600	O

0	O
.	O
0197	O

50	O

Random	O
forest	O

0	O
.	O
1115	O

0	O
.	O
0792	O

Random	O

0	O
.	O
0734	O

0	O
.	O
0283	O

Table	O
shows	O
area	O
under	O
the	O
precision	O
recall	O
curve	O
(	O
AUPR	O
)	O
and	O
R50	O
that	O
measures	O
the	O
area	O
under	O
the	O
precision	O
-	O
recall	O
curve	O
until	O
reaching	O
50	O
negative	O
predictions	O
.	O

We	O
see	O
that	O
node	O
and	O
edge	O
centrality	O
of	O
an	O
interaction	O
do	O
indeed	O
correlate	O
with	O
how	O
much	O
impact	O
an	O
interaction	O
can	O
make	O
on	O
furthering	O
biomedical	O
science	O
.	O

We	O
assess	O
feature	O
importance	O
based	O
on	O
the	O
Gini	O
index	O
of	O
the	O
random	O
forest	O
classifier	O
.	O

The	O
result	O
is	O
shown	O
in	O
Figures	O
6	O
and	O
7	O
.	O

All	O
of	O
the	O
topology	O
based	O
features	O
are	O
moderately	O
informative	O
,	O
but	O
there	O
are	O
no	O
distinctively	O
dominant	O
features	O
.	O

Prior	O
research	O
has	O
often	O
connected	O
a	O
node	O
’	O
s	O
degree	O
centrality	O
with	O
its	O
essentiality	O
;	O
however	O
,	O
when	O
considering	O
future	O
biomedical	O
impact	O
,	O
we	O
see	O
that	O
degree	O
centrality	O
is	O
the	O
least	O
indicative	O
feature	O
out	O
of	O
all	O
other	O
topology	O
based	O
features	O
.	O

Temporal	O
citation	O
patterns	O
.	O

Random	O
Forest	O
Gini	O
importance	O
measures	O
for	O
each	O
feature	O
.	O

High	O
-	O
impact	O
edges	O
in	O
the	O
human	B-OG
interactome	O

After	O
carrying	O
out	O
the	O
evaluations	O
described	O
earlier	O
,	O
the	O
method	O
was	O
applied	O
to	O
identify	O
high	O
impact	O
edges	O
from	O
amongst	O
all	O
the	O
PPIs	O
in	O
the	O
human	B-OG
interactome	O
.	O

A	O
final	O
model	O
was	O
trained	O
with	O
all	O
available	O
interactions	O
that	O
have	O
a	O
one	O
-	O
to	O
-	O
one	O
relationship	O
with	O
a	O
paper	O
(	O
i	O
.	O
e	O
.,	O
including	O
those	O
that	O
were	O
originally	O
left	O
out	O
for	O
evaluation	O
purposes	O
).	O

The	O
model	O
was	O
then	O
applied	O
to	O
identify	O
high	O
-	O
impact	O
PPIs	O
from	O
amongst	O
all	O
the	O
PPIs	O
in	O
the	O
interactome	O
.	O

Note	O
here	O
,	O
that	O
the	O
model	O
was	O
applied	O
on	O
all	O
the	O
PPIs	O
without	O
restricting	O
to	O
those	O
that	O
have	O
one	O
-	O
to	O
-	O
one	O
relationship	O
with	O
publications	O
;	O
such	O
a	O
dataset	O
is	O
required	O
only	O
for	O
training	O
the	O
model	O
accurately	O
and	O
to	O
evaluate	O
the	O
model	O
reliably	O
,	O
whereas	O
,	O
the	O
final	O
prediction	O
of	O
whether	O
a	O
PPI	O
is	O
of	O
high	O
impact	O
is	O
carried	O
out	O
based	O
on	O
its	O
network	O
features	O
alone	O
without	O
dependence	O
on	O
the	O
number	O
of	O
times	O
it	O
has	O
been	O
reported	O
.	O

Table	O
4	O
lists	O
the	O
top	O
10	O
PPIs	O
that	O
are	O
predicted	O
to	O
be	O
of	O
high	O
impact	O
.	O

As	O
can	O
be	O
seen	O
,	O
most	O
of	O
them	O
indeed	O
resulted	O
in	O
high	O
impact	O
on	O
biomedical	O
science	O
,	O
resulting	O
in	O
up	O
to	O
413	O
citations	O
.	O

The	O
top	O
100	O
most	O
-	O
impactful	O
edges	O
of	O
human	B-OG
interactome	O
predicted	O
by	O
this	O
model	O
are	O
given	O
in	O
Additional	O
file	O
1	O
.	O

While	O
these	O
PPIs	O
are	O
predicted	O
to	O
be	O
of	O
high	O
impact	O
,	O
the	O
actual	O
impact	O
achieved	O
by	O
each	O
of	O
these	O
PPIs	O
may	O
be	O
seen	O
on	O
Wiki	O
-	O
Pi	O
web	O
server	O
,	O
which	O
shows	O
up	O
-	O
to	O
-	O
date	O
information	O
on	O
the	O
number	O
of	O
citations	O
received	O
by	O
the	O
publication	O
which	O
reports	O
the	O
PPI	O
[	O
42	O
].	O

The	O
top	O
10	O
interactions	O
that	O
are	O
predicted	O
to	O
be	O
of	O
high	O
impact	O

PPI	O
information	O

Publication	O
information	O

Rank	O
by	O
impact	O

Gene	O
symbols	O

Protein	O
A	O
name	O

Protein	O
B	O
name	O

Pubmed	O
ID	O

Number	O
of	O
citations	O
so	O
far	O

Year	O
of	O
publication	O

1	O

ADIPOQ	B-GP
-	O
ADIPOR2	B-GP

adiponectin	B-GP
,	I-GP
C1Q	I-GP
and	I-GP
collagen	I-GP
domain	I-GP
containing	I-GP

adiponectin	B-GP
receptor	I-GP
2	I-GP

12802337	O

160	O

2003	O

2	O

NMB	B-GP
-	O
NMBR	B-GP

neuromedin	B-GP
B	I-GP

neuromedin	B-GP
B	I-GP
receptor	I-GP

8392057	O

8	O

1993	O

3	O

NUP93	B-GP
-	O
TMEM48	B-GP

nucleoporin	B-GP
93	I-GP
k	O
Da	O

transmembrane	B-GP
protein	I-GP
48	I-GP

12928435	O

37	O

2006	O

4	O

DAO	B-GP
-	O
DAOA	B-GP

D	B-GP
-	I-GP
amino	I-GP
-	I-GP
acid	I-GP
oxidase	I-GP

D	B-GP
-	I-GP
amino	I-GP
acid	I-GP
oxidase	I-GP
activator	I-GP

12364586	O

72	O

2002	O

5	O

PCM1	B-GP
-	O
TIC8	O

pericentriolar	B-GP
material	I-GP
1	I-GP

tetratricopeptide	B-GP
repeat	I-GP
domain	I-GP
8	I-GP

14520415	O

99	O

2003	O

6	O

PCM1	B-GP
-	O
KIAA0368	B-GP

pericentriolar	B-GP
material	I-GP
1	I-GP

KIAA0368	B-GP

16189514	O

413	O

2005	O

7	O

BBS4	B-GP
-	O
PCM1	B-GP

Bardet	B-GP
-	I-GP
Biedl	I-GP
syndrome	I-GP
4	I-GP

pericentriolar	B-GP
material	I-GP
1	I-GP

15107855	O

55	O

2004	O

8	O

SRC	B-GP
-	O
YWHAG	B-GP

v	B-GP
-	I-GP
src	I-GP
sarcoma	I-GP
(	I-GP
Schmidt	I-GP
-	I-GP
Ruppin	I-GP
A	I-GP
-	I-GP
2	I-GP
)	I-GP
viral	I-GP
oncogene	I-GP
homolog	I-GP
(	O
avian	O
)	O

tyrosine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
/	I-GP
tryptophan	I-GP
5	I-GP
-	I-GP
monooxygenase	I-GP
activation	I-GP
protein	I-GP
,	I-GP
gamma	I-GP
polypeptide	I-GP

8702721	O

21	O

1996	O

9	O

GRB2	B-GP
-	O
SRC	B-GP

growth	B-GP
factor	I-GP
receptor	I-GP
-	I-GP
bound	I-GP
protein	I-GP
2	I-GP

v	B-GP
-	I-GP
src	I-GP
sarcoma	I-GP
(	I-GP
Schmidt	I-GP
-	I-GP
Ruppin	I-GP
A	I-GP
-	I-GP
2	I-GP
)	I-GP
viral	I-GP
oncogene	I-GP
homolog	I-GP
(	O
avian	O
)	O

11964172	O

2	O

2002	O

10	O

HCN2	B-GP
-	O
HCN4	B-GP

hyperpolarization	B-GP
activated	I-GP
cyclic	I-GP
nucleotide	I-GP
-	I-GP
gated	I-GP
potassium	I-GP
channel	I-GP
2	I-GP

hyperpolarization	B-GP
activated	I-GP
cyclic	I-GP
nucleotide	I-GP
-	I-GP
gated	I-GP
potassium	I-GP
channel	I-GP
4	I-GP

12928435	O

26	O

2003	O

Note	O
that	O
for	O
each	O
interaction	O
,	O
we	O
only	O
show	O
the	O
publication	O
that	O
has	O
the	O
highest	O
citation	O
count	O
among	O
those	O
that	O
report	O
the	O
said	O
interaction	O
.	O

Functional	O
enrichment	O
of	O
high	O
-	O
impact	O
interactions	O

We	O
analyzed	O
the	O
statistical	O
enrichment	O
of	O
annotations	O
of	O
the	O
interactions	O
that	O
are	O
predicted	O
to	O
be	O
high	O
-	O
impact	O
.	O

The	O
Gene	O
Ontology	O
term	O
enrichment	O
for	O
proteins	O
involved	O
in	O
the	O
top	O
50	O
high	O
-	O
impact	O
interactions	O
has	O
been	O
computed	O
using	O
the	O
BiNGO	O
plugin	O
for	O
Cytoscape	O
[	O
43	O
].	O

This	O
analysis	O
revealed	O
enrichment	O
in	O
80	O
biological	O
processes	O
,	O
16	O
molecular	O
functions	O
,	O
and	O
25	O
cellular	O
component	O
terms	O
at	O
a	O
statistical	O
significance	O
of	O
P	O
<	O
0	O
.	O
05	O
(	O
see	O
Additional	O
files	O
2	O
,	O
3	O
and	O
4	O
respectively	O
in	O
text	O
format	O
,	O
and	O
Additional	O
files	O
5	O
,	O
6	O
and	O
7	O
respectively	O
in	O
Cytoscape	O
format	O
).	O

For	O
example	O
,	O
cell	O
cycle	O
,	O
negative	O
regulation	O
of	O
biological	O
process	O
,	O
and	O
initiation	O
of	O
DNA	O
-	O
dependent	O
transcription	O
are	O
highly	O
enriched	O
biological	O
process	O
terms	O
,	O
while	O
protein	O
-	O
binding	O
transcription	O
factor	O
activity	O
and	O
transcription	O
-	O
factor	O
binding	O
are	O
the	O
highly	O
represented	O
molecular	O
function	O
terms	O
,	O
and	O
nuclear	O
part	O
,	O
membrane	O
-	O
enclosed	O
lumen	O
,	O
and	O
macromolecular	O
complex	O
are	O
the	O
top	O
most	O
significant	O
cellular	O
components	O
.	O

High	O
impact	O
interactions	O
of	O
GWAS	O
genes	O

Genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
provide	O
a	O
mapping	O
between	O
genetic	O
factors	O
and	O
diseases	O
by	O
drawing	O
comparisons	O
in	O
the	O
genotype	O
of	O
variants	O
between	O
disease	O
cases	O
and	O
controls	O
.	O

These	O
studies	O
are	O
unbiased	O
by	O
current	O
scientific	O
knowledge	O
about	O
individual	O
genes	O
(	O
i	O
.	O
e	O
.,	O
they	O
do	O
not	O
have	O
literature	O
-	O
bias	O
),	O
and	O
identify	O
genome	O
regions	O
with	O
previously	O
unknown	O
biological	O
relevance	O
and	O
provide	O
replicable	O
results	O
[	O
44	O
].	O

They	O
often	O
uncover	O
several	O
genes	O
of	O
unknown	O
functions	O
possibly	O
participating	O
in	O
hitherto	O
unknown	O
biological	O
pathways	O
[	O
44	O
].	O

We	O
collected	O
the	O
catalog	O
of	O
GWAS	O
studies	O
which	O
is	O
maintained	O
by	O
National	O
Human	B-OG
Genome	O
Research	O
Institute	O
(	O
NHGRI	O
)	O
[	O
45	O
,	O
46	O
].	O

This	O
catalog	O
contains	O
1	O
,	O
309	O
publications	O
reporting	O
GWAS	O
results	O
on	O
674	O
traits	O
or	O
diseases	O
.	O

We	O
investigated	O
whether	O
any	O
high	O
-	O
impact	O
interactions	O
belong	O
to	O
those	O
that	O
are	O
associated	O
with	O
diseases	O
(	O
as	O
identified	O
by	O
GWAS	O
;	O
henceforth	O
referred	O
to	O
as	O
GWAS	O
-	O
genes	O
)	O
[	O
46	O
].	O

Retinal	O
vascular	O
caliber	O
,	O
type	B-DS
2	I-DS
diabetes	I-DS
,	O
and	O
glioma	B-DS
are	O
some	O
of	O
the	O
diseases	O
associated	O
with	O
the	O
genes	O
in	O
the	O
top	O
100	O
high	O
-	O
impact	O
interactions	O
.	O

Of	O
the	O
top	O
50	O
high	O
-	O
impact	O
interactions	O
,	O
those	O
in	O
which	O
one	O
or	O
both	O
proteins	O
are	O
among	O
the	O
GWAS	O
-	O
genes	O
are	O
shown	O
in	O
Table	O
5	O
and	O
a	O
larger	O
list	O
is	O
available	O
in	O
Additional	O
file	O
8	O
.	O

GWAS	O
genes	O
in	O
the	O
top	O
50	O
high	O
-	O
impact	O
interactions	O


Publication	O
information	O

Information	O
about	O
genes	O
involved	O
in	O
the	O
PPI	O

Rank	O

PMID	O

Cite	O
count	O

Pub	O
year	O

Symbol	O
1	O

Symbol	O
2	O

Name	O
1	O

Name	O
2	O

GWAS	O
diseases	O
/	O
traits	O
of	O
1	O

GWAS	O
diseases	O
/	O
traits	O
of	O
2	O

1	O

12802337	O

160	O

2003	O

ADIPOQ	B-GP

ADIPOR2	B-GP

adiponectin	B-GP
,	I-GP
C1Q	I-GP
and	I-GP
collagen	I-GP
domain	I-GP
containing	I-GP

adiponectin	B-GP
receptor	I-GP
2	I-GP

adiponectin	B-GP
levels	O


2	O

8392057	O

8	O

1993	O

NMB	B-GP

NMBR	B-GP

neuromedin	B-GP
B	I-GP

neuromedin	B-GP
B	I-GP
receptor	I-GP


Retinal	O
vascular	O
caliber	O

3	O

16600873	O

37	O

2006	O

NUP93	B-GP

TMEM48	B-GP

nucleoporin	B-GP
93	I-GP
kDa	O

transmembrane	B-GP
protein	I-GP
48	I-GP

HDL	O
cholesterol	O


4	O

12364586	O

72	O

2002	O

DAO	B-GP

DAOA	B-GP

D	B-GP
-	I-GP
amino	I-GP
-	I-GP
acid	I-GP
oxidase	I-GP

D	B-GP
-	I-GP
amino	I-GP
acid	I-GP
oxidase	I-GP
activator	I-GP


Bipolar	O
disorder	O
and	O
schizophrenia	B-DS

8	O

8702721	O

21	O

1996	O

SRC	B-GP

YWHAG	B-GP

v	B-GP
-	I-GP
src	I-GP
sarcoma	I-GP
(	I-GP
Schmidt	I-GP
-	I-GP
Ruppin	I-GP
A	I-GP
-	I-GP
2	I-GP
)	I-GP
viral	I-GP
oncogene	I-GP
homolog	I-GP
(	O
avian	O
)	O

tyrosine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
/	I-GP
tryptophan	I-GP
5	I-GP
-	I-GP
monooxygenase	I-GP
activation	I-GP
protein	I-GP
,	I-GP
gamma	I-GP
polypeptide	I-GP


Multiple	B-DS
sclerosis	I-DS

12	O

2996780	O

64	O

1985	O

PRKCA	B-GP

SRC	B-GP

protein	B-GP
kinase	I-GP
C	I-GP
,	I-GP
alpha	I-GP

v	B-GP
-	I-GP
src	I-GP
sarcoma	I-GP
(	I-GP
Schmidt	I-GP
-	I-GP
Ruppin	I-GP
A	I-GP
-	I-GP
2	I-GP
)	I-GP
viral	I-GP
oncogene	I-GP
homolog	I-GP
(	O
avian	O
)	O

Ventricular	O
conduction	O
,	O
Height	O


14	O

10766163	O

6	O

2000	O

ESR1	B-GP

TP53	B-GP

estrogen	B-GP
receptor	I-GP
1	I-GP

tumor	B-GP
protein	I-GP
p53	I-GP

Bone	O
mineral	O
density	O
(	O
hip	O
),	O
Height	O
,	O
Alcohol	B-DS
dependence	I-DS
,	O
Sudden	B-DS
cardiac	I-DS
arrest	I-DS
,	O
Bone	O
mineral	O
density	O
(	O
spine	O
),	O
Chronic	B-DS
myeloid	I-DS
leukemia	I-DS
,	O
Breast	B-DS
cancer	I-DS


15	O

15173068	O

8	O

2004	O

ESR1	B-GP

GRB2	B-GP

estrogen	B-GP
receptor	I-GP
1	I-GP

growth	B-GP
factor	I-GP
receptor	I-GP
-	I-GP
bound	I-GP
protein	I-GP
2	I-GP

Bone	O
mineral	O
density	O
(	O
hip	O
),	O
Height	O
,	O
Alcohol	B-DS
dependence	I-DS
,	O
Sudden	B-DS
cardiac	I-DS
arrest	I-DS
,	O
Bone	O
mineral	O
density	O
(	O
spine	O
),	O
Chronic	B-DS
myeloid	I-DS
leukemia	I-DS
,	O
Breast	B-DS
cancer	I-DS


16	O

9568714	O

278	O

1998	O

GATA4	O

NFATC4	B-GP

GATA	B-GP
binding	I-GP
protein	I-GP
4	I-GP

nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
-	I-GP
cells	I-GP
,	I-GP
cytoplasmic	I-GP
,	I-GP
calcineurin	I-GP
-	I-GP
dependent	I-GP
4	I-GP

Retinal	O
vascular	O
caliber	O

Height	O

17	O

10433554	O

4	O

1999	O

PRKCA	B-GP

YWHAG	B-GP

protein	B-GP
kinase	I-GP
C	I-GP
,	I-GP
alpha	I-GP

tyrosine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
/	I-GP
tryptophan	I-GP
5	I-GP
-	I-GP
monooxygenase	I-GP
activation	I-GP
protein	I-GP
,	I-GP
gamma	I-GP
polypeptide	I-GP

Ventricular	O
conduction	O
,	O
Height	O

Multiple	B-DS
sclerosis	I-DS

18	O

8266076	O

105	O

1993	O

IL2RG	B-GP

IL4R	B-GP

interleukin	B-GP
2	I-GP
receptor	I-GP
,	I-GP
gamma	I-GP

interleukin	B-GP
4	I-GP
receptor	I-GP


IgE	O
levels	O

22	O

12732139	O

46	O

2003	O

SMAD3	O

TP53	B-GP

SMAD	O
family	O
member	O
3	O

tumor	B-GP
protein	I-GP
p53	I-GP

Coronary	B-DS
heart	I-DS
disease	I-DS
,	O
Asthma	B-DS
,	O
Crohn	B-DS
'	I-DS
s	I-DS
disease	I-DS


23	O

1454855	O

45	O

1992	O

PRKCA	B-GP

TP53	B-GP

protein	B-GP
kinase	I-GP
C	I-GP
,	I-GP
alpha	I-GP

tumor	B-GP
protein	I-GP
p53	I-GP

Ventricular	O
conduction	O
,	O
Height	O


24	O

8266077	O

115	O

1993	O

IL2RG	B-GP

IL7R	B-GP

interleukin	B-GP
2	I-GP
receptor	I-GP
,	I-GP
gamma	I-GP

interleukin	B-GP
7	I-GP
receptor	I-GP


Type	B-DS
1	I-DS
diabetes	I-DS
,	O
Ulcerative	B-DS
colitis	I-DS
,	O
Multiple	B-DS
sclerosis	I-DS
,	O
Primary	B-DS
biliary	I-DS
cirrhosis	I-DS

28	O

15324660	O

72	O

2004	O

TP53	B-GP

YWHAG	B-GP

tumor	B-GP
protein	I-GP
p53	I-GP

tyrosine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
/	I-GP
tryptophan	I-GP
5	I-GP
-	I-GP
monooxygenase	I-GP
activation	I-GP
protein	I-GP
,	I-GP
gamma	I-GP
polypeptide	I-GP


Multiple	B-DS
sclerosis	I-DS

31	O

15140878	O

17	O

2004	O

ESR1	B-GP

SRC	B-GP

estrogen	B-GP
receptor	I-GP
1	I-GP

v	B-GP
-	I-GP
src	I-GP
sarcoma	I-GP
(	I-GP
Schmidt	I-GP
-	I-GP
Ruppin	I-GP
A	I-GP
-	I-GP
2	I-GP
)	I-GP
viral	I-GP
oncogene	I-GP
homolog	I-GP
(	O
avian	O
)	O

Bone	O
mineral	O
density	O
(	O
hip	O
),	O
Height	O
,	O
Alcohol	B-DS
dependence	I-DS
,	O
Sudden	B-DS
cardiac	I-DS
arrest	I-DS
,	O
Bone	O
mineral	O
density	O
(	O
spine	O
),	O
Chronic	B-DS
myeloid	I-DS
leukemia	I-DS
,	O
Breast	B-DS
cancer	I-DS


34	O

12878187	O

1	O

2003	O

EGFR	B-GP

PRKCA	B-GP

epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP

protein	B-GP
kinase	I-GP
C	I-GP
,	I-GP
alpha	I-GP

Glioma	B-DS

Ventricular	O
conduction	O
,	O
Height	O

36	O

16192271	O

88	O

2005	O

ABCA1	O

DLG3	B-GP

ATP	B-GP
-	I-GP
binding	I-GP
cassette	I-GP
,	I-GP
sub	I-GP
-	I-GP
family	I-GP
A	I-GP
(	I-GP
ABC1	I-GP
),	I-GP
member	I-GP
1	I-GP

discs	O
,	O
large	O
homolog	O
3	O
(	O
Drosophila	B-OG
)	O

MRI	O
atrophy	O
measures	O
,	O
HDL	O
cholesterol	O
,	O
Lipid	O
metabolism	O
phenotypes	O
,	O
Cholesterol	O
,	O
total	O
,	O
Coronary	B-DS
heart	I-DS
disease	I-DS


38	O

17057718	O

66	O

2006	O

GATA3	O

SATB1	B-GP

GATA	O
binding	O
protein	O
3	O

SATB	B-GP
homeobox	I-GP
1	I-GP

Hodgkin	O
'	O
s	O
lymphoma	O

Platelet	O
counts	O

39	O

15466214	O

27	O

2004	O

AR	O

SRC	B-GP

androgen	B-GP
receptor	I-GP

v	B-GP
-	I-GP
src	I-GP
sarcoma	I-GP
(	I-GP
Schmidt	I-GP
-	I-GP
Ruppin	I-GP
A	I-GP
-	I-GP
2	I-GP
)	I-GP
viral	I-GP
oncogene	I-GP
homolog	I-GP
(	O
avian	O
)	O

Prostate	B-DS
cancer	I-DS
,	O
Male	B-DS
-	I-DS
pattern	I-DS
baldness	I-DS
,	O
LDL	O
cholesterol	O


44	O

8994038	O

82	O

1997	O

GRB2	B-GP

MAPK1	B-GP

growth	B-GP
factor	I-GP
receptor	I-GP
-	I-GP
bound	I-GP
protein	I-GP
2	I-GP

mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
1	I-GP


Multiple	B-DS
sclerosis	I-DS

46	O

11782371	O

15	O

2002	O

EP300	O

ESR1	B-GP

E1A	O
binding	O
protein	O
p300	O

estrogen	B-GP
receptor	I-GP
1	I-GP


Bone	O
mineral	O
density	O
(	O
hip	O
),	O
Height	O
,	O
Alcohol	B-DS
dependence	I-DS
,	O
Sudden	B-DS
cardiac	I-DS
arrest	I-DS
,	O
Bone	O
mineral	O
density	O
(	O
spine	O
),	O
Chronic	B-DS
myeloid	I-DS
leukemia	I-DS
,	O
Breast	B-DS
cancer	I-DS

47	O

12200137	O

1	O

2002	O

IL2RG	B-GP

SHB	B-GP

interleukin	B-GP
2	I-GP
receptor	I-GP
,	I-GP
gamma	I-GP

Src	B-GP
homology	I-GP
2	I-GP
domain	I-GP
containing	I-GP
adaptor	I-GP
protein	I-GP
B	I-GP


Brain	O
structure	O

50	O

7477400	O

72	O

1995	O

HLA	O
-	O
DRB3	O

POMC	B-GP

major	O
histocompatibility	O
complex	O
,	O
class	O
II	O
,	O
DR	O
beta	O
3	O

proopiomelanocortin	B-GP


Type	B-DS
1	I-DS
diabetes	I-DS
,	O
Height	O
,	O
Body	O
mass	O
index	O

Of	O
the	O
top	O
50	O
high	O
impact	O
interactions	O
,	O
those	O
in	O
which	O
one	O
or	O
both	O
genes	O
are	O
found	O
to	O
be	O
associated	O
with	O
a	O
disease	O
or	O
trait	O
by	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
are	O
shown	O
.	O

GWAS	O
associated	O
genes	O
are	O
shown	O
in	O
bold	O
.	O

Open	O
challenges	O

Inferring	O
biological	O
conclusions	O
from	O
topology	O
of	O
a	O
partially	O
-	O
known	O
network	O
will	O
be	O
influenced	O
by	O
the	O
sampling	O
biases	O
that	O
can	O
alter	O
the	O
underlying	O
structure	O
of	O
the	O
network	O
in	O
unpredictable	O
ways	O
[	O
47	O
].	O

As	O
mentioned	O
earlier	O
,	O
only	O
10	O
%	O
of	O
the	O
human	B-OG
interactome	O
is	O
currently	O
known	O
.	O

The	O
fact	O
that	O
we	O
are	O
dealing	O
with	O
a	O
sub	O
-	O
network	O
,	O
rather	O
than	O
a	O
complete	O
network	O
presents	O
an	O
inherent	O
challenge	O
to	O
this	O
study	O
.	O

The	O
first	O
issue	O
concerns	O
the	O
accuracy	O
of	O
the	O
centrality	O
measures	O
:	O
under	O
-	O
studied	O
sub	O
-	O
regions	O
of	O
the	O
network	O
may	O
have	O
superficially	O
low	O
centrality	O
measures	O
,	O
while	O
well	O
-	O
studied	O
sub	O
-	O
regions	O
of	O
the	O
network	O
may	O
have	O
seemingly	O
high	O
centrality	O
measures	O
.	O

The	O
second	O
issue	O
involves	O
bias	O
in	O
the	O
citation	O
behavior	O
:	O
well	O
-	O
studied	O
sub	O
-	O
regions	O
,	O
by	O
definition	O
,	O
are	O
more	O
avidly	O
studied	O
.	O

Thus	O
,	O
it	O
may	O
be	O
the	O
case	O
that	O
well	O
-	O
studied	O
sub	O
-	O
regions	O
will	O
contain	O
highly	O
-	O
cited	O
interactions	O
due	O
to	O
study	O
bias	O
.	O

In	O
order	O
to	O
address	O
this	O
inaccuracy	O
in	O
centrality	O
measures	O
and	O
sociological	O
bias	O
in	O
the	O
citation	O
counts	O
,	O
constructing	O
a	O
network	O
from	O
systematic	O
,	O
unbiased	O
high	O
-	O
throughput	O
experiments	O
(	O
biotechnological	O
or	O
computational	O
methods	O
)	O
is	O
one	O
area	O
of	O
future	O
research	O
.	O

Impact	O
prediction	O
in	O
any	O
biological	O
domain	O
in	O
general	O
,	O
has	O
unique	O
challenges	O
.	O

Unlike	O
in	O
other	O
computational	O
domains	O
,	O
such	O
as	O
human	B-OG
language	O
translation	O
,	O
it	O
is	O
difficult	O
to	O
estimate	O
the	O
translational	O
impact	O
in	O
biology	O
in	O
a	O
particular	O
study	O
because	O
it	O
is	O
time	O
consuming	O
and	O
requires	O
investment	O
of	O
expensive	O
resources	O
and	O
scientific	O
skills	O
making	O
the	O
design	O
of	O
such	O
algorithms	O
challenging	O
.	O

Despite	O
its	O
difficulties	O
,	O
the	O
proposed	O
direction	O
of	O
research	O
of	O
developing	O
inference	O
-	O
analytic	O
algorithms	O
is	O
necessary	O
to	O
make	O
advances	O
in	O
the	O
most	O
impactful	O
direction	O
.	O

Potential	O
implications	O

High	O
-	O
throughput	O
biotechnology	O
and	O
computational	O
prediction	O
algorithms	O
generate	O
a	O
plethora	O
of	O
hypothesized	O
biological	O
inferences	O
.	O

Meanwhile	O
,	O
high	O
-	O
resolution	O
bench	O
work	O
experiments	O
in	O
biology	O
are	O
often	O
carried	O
out	O
by	O
formulating	O
the	O
hypothesis	O
with	O
a	O
local	O
view	O
of	O
a	O
molecule	O
rather	O
than	O
a	O
systemic	O
view	O
.	O

In	O
this	O
era	O
of	O
scalable	O
data	O
-	O
analytic	O
algorithms	O
which	O
process	O
large	O
data	O
,	O
producing	O
hundreds	O
of	O
inferences	O
,	O
there	O
needs	O
to	O
be	O
a	O
systematic	O
way	O
of	O
determining	O
which	O
of	O
these	O
hundreds	O
of	O
inferences	O
are	O
to	O
be	O
further	O
studied	O
.	O

In	O
this	O
position	O
paper	O
,	O
we	O
propose	O
a	O
new	O
class	O
of	O
algorithms	O
called	O
inference	O
-	O
analytic	O
algorithms	O
that	O
carry	O
out	O
such	O
systematic	O
analysis	O
to	O
prioritize	O
the	O
computational	O
inferences	O
for	O
further	O
study	O
;	O
the	O
concept	O
has	O
been	O
demonstrated	O
in	O
the	O
context	O
of	O
protein	O
-	O
protein	O
interactions	O
(	O
PPIs	O
).	O

The	O
algorithm	O
is	O
designed	O
to	O
provide	O
a	O
roadmap	O
for	O
the	O
order	O
in	O
which	O
PPIs	O
should	O
be	O
studied	O
further	O
,	O
in	O
the	O
hope	O
that	O
this	O
will	O
prioritize	O
the	O
investment	O
of	O
small	O
-	O
scale	O
experiments	O
and	O
reap	O
maximum	O
benefit	O
for	O
the	O
field	O
of	O
biomedicine	O
as	O
a	O
whole	O
.	O

It	O
has	O
the	O
potential	O
to	O
identify	O
both	O
existing	O
PPIs	O
with	O
untapped	O
impact	O
and	O
also	O
newly	O
predicted	O
PPIs	O
with	O
potential	O
for	O
impact	O
.	O

Factors	O
such	O
as	O
disease	O
-	O
associations	O
and	O
drug	O
-	O
binding	O
also	O
determine	O
which	O
proteins	O
are	O
to	O
be	O
studied	O
further	O
for	O
biomedical	O
impact	O
.	O

On	O
the	O
other	O
hand	O
,	O
factors	O
such	O
as	O
unavailability	O
of	O
reagents	O
may	O
restrict	O
the	O
study	O
of	O
some	O
of	O
these	O
proteins	O
.	O

Future	O
algorithmic	O
prediction	O
of	O
impactful	O
PPIs	O
needs	O
to	O
incorporate	O
these	O
preferences	O
and	O
constraints	O
.	O

Identifying	O
high	O
-	O
impact	O
PPIs	O
brings	O
the	O
focus	O
of	O
the	O
scientific	O
community	O
onto	O
these	O
proteins	O
and	O
fuels	O
the	O
development	O
of	O
necessary	O
skills	O
,	O
reagents	O
,	O
and	O
so	O
forth	O
.	O

Availability	O
of	O
supporting	O
data	O

Supporting	O
data	O
are	O
made	O
available	O
on	O
BiomedCentral	O
website	O
as	O
described	O
under	O
Additional	O
files	O
section	O
.	O

Abbreviations	O

PPI	O
:	O
Protein	O
-	O
protein	O
interaction	O
;	O
MeSH	O
:	O
Medical	O
subject	O
heading	O
;	O
ROC	O
:	O
Receiver	O
operating	O
characteristics	O
;	O
AUPR	O
:	O
Area	O
under	O
the	O
precision	O
-	O
recall	O
curve	O
;	O
GWAS	O
:	O
Genome	O
-	O
wide	O
association	O
studies	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
’	O
contributions	O

The	O
concept	O
and	O
the	O
design	O
were	O
developed	O
by	O
MKG	O
.	O

The	O
implementation	O
was	O
carried	O
out	O
by	O
NO	O
.	O

The	O
analyses	O
were	O
carried	O
out	O
by	O
MKG	O
and	O
NO	O
.	O

The	O
manuscript	O
is	O
written	O
by	O
MKG	O
with	O
inputs	O
from	O
NO	O
.	O

Both	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Authors	O
’	O
information	O

Madhavi	O
K	O
.	O

Ganapathiraju	O
has	O
Ph	O
.	O
D	O
.	O
from	O
the	O
Language	O
Technologies	O
Institute	O
,	O
Carnegie	O
Mellon	O
University	O
School	O
of	O
Computer	O
Science	O
,	O
and	O
Master	O
’	O
s	O
degree	O
in	O
Electrical	O
Communications	O
Engineering	O
from	O
the	O
Indian	O
Institute	O
Science	O
.	O

She	O
is	O
Faculty	O
in	O
Biomedical	O
Informatics	O
and	O
Intelligent	O
Systems	O
at	O
University	O
of	O
Pittsburgh	O
,	O
where	O
she	O
is	O
applying	O
computational	O
methods	O
to	O
discover	O
hitherto	O
unknown	O
protein	O
-	O
protein	O
interactions	O
in	O
the	O
human	B-OG
interactome	O
.	O

Naoki	O
Orii	O
was	O
graduate	O
student	O
at	O
the	O
Language	O
Technologies	O
Institute	O
,	O
Carnegie	O
Mellon	O
University	O
School	O
of	O
Computer	O
Science	O
when	O
he	O
carried	O
out	O
this	O
work	O
.	O

Subsequent	O
to	O
obtaining	O
his	O
Master	O
’	O
s	O
degree	O
in	O
May	O
2013	O
,	O
he	O
moved	O
to	O
the	O
data	O
-	O
analytics	O
industry	O
.	O

Supplementary	O
Material	O

Additional	O
file	O
1	O

100	O
most	O
-	O
impactful	O
interactions	O
as	O
predicted	O
by	O
the	O
model	O
,	O
as	O
well	O
as	O
predicted	O
impact	O
scores	O
for	O
all	O
interactions	O
sorted	O
in	O
descending	O
order	O
by	O
predicted	O
impact	O
.	O

Click	O
here	O
for	O
file	O

Additional	O
file	O
2	O

Enriched	O
Gene	O
Ontology	O
terms	O
(	O
biological	O
process	O
)	O
for	O
the	O
top	O
50	O
high	O
-	O
impact	O
interactions	O
.	O

Click	O
here	O
for	O
file	O

Additional	O
file	O
3	O

Enriched	O
Gene	O
Ontology	O
terms	O
(	O
molecular	O
function	O
)	O
for	O
the	O
top	O
50	O
high	O
-	O
impact	O
interactions	O
.	O

Click	O
here	O
for	O
file	O

Additional	O
file	O
4	O

Enriched	O
Gene	O
Ontology	O
terms	O
(	O
cellular	O
component	O
)	O
for	O
the	O
top	O
50	O
high	O
-	O
impact	O
interactions	O
.	O

Click	O
here	O
for	O
file	O

Additional	O
file	O
5	O

Cytoscape	O
session	O
file	O
showing	O
enriched	O
Gene	O
Ontology	O
biological	O
process	O
terms	O
,	O
output	O
by	O
BiNGO	O
.	O

Click	O
here	O
for	O
file	O

Additional	O
file	O
6	O

Cytoscape	O
session	O
file	O
showing	O
enriched	O
Gene	O
Ontology	O
molecular	O
function	O
terms	O
,	O
output	O
by	O
BiNGO	O
.	O

Click	O
here	O
for	O
file	O

Additional	O
file	O
7	O

Cytoscape	O
session	O
file	O
showing	O
enriched	O
Gene	O
Ontology	O
cellular	O
component	O
terms	O
,	O
output	O
by	O
BiNGO	O
.	O

Click	O
here	O
for	O
file	O

Additional	O
file	O
8	O

Of	O
the	O
top	O
50	O
high	O
-	O
impact	O
interactions	O
,	O
those	O
in	O
which	O
one	O
or	O
both	O
proteins	O
are	O
among	O
the	O
GWAS	O
-	O
genes	O
are	O
shown	O
.	O

Click	O
here	O
for	O
file	O

